Cannell & Co’s Petros Pharmaceuticals PTPI Stock Holding History

Cannell & Co’s Portfolio PTPI Stock Details PTPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-102	Closed	-$112K	–	288
2020 Q4	$112K	Buy	+102	New	+$96K	﹤0.01%	264

Other funds holding PTPI

NorthRock Partners Minneapolis, Minnesota $6.2B AUM 15.8% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFAS

Acorn Financial Advisory Services Reston, Virginia $753M AUM 36.94% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Cannell & Co's PTPI Position: Q1 2021 in Review

Cannell & Co sold out of Petros Pharmaceuticals (PTPI) in Q1 2021, closing a stake of 102 shares — an estimated $112K sold.

Cannell & Co first reported a position in PTPI in Q4 2020 and held it in 1 quarter. The position peaked at $112K in Q4 2020. 17 funds tracked by Wall St. Rank hold PTPI as of Q1 2021.

Cannell & Co reported no remaining Petros Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Cannell & Co sold 102 Petros Pharmaceuticals shares in Q1 2021, an estimated $112K.
Cannell & Co first reported a position in Petros Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Cannell & Co's Petros Pharmaceuticals position peaked at $112K in Q4 2020.
17 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q1 2021.

Based on Cannell & Co's 13F filing for Q1 2021, filed 7 May 2021.